Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;46(6):517-532.
doi: 10.1007/s40264-023-01285-5. Epub 2023 May 23.

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

Priya Bahri  1   2 , Geoffrey Bowring  3   4 , Brian D Edwards  3   5 , Christopher Anton  3   6 , Jeffrey K Aronson  7 , Angela Caro-Rojas  3   8 , Bruce P J Hugman  9 , Peter G Mol  3   10 , Gianluca Trifirò  11 , Katarina Ilic  3   12 , Riadh Daghfous  13 , Irene Fermont  14 , Giovanni Furlan  3   15 , Wolfgang Gaissmaier  16 , Mohammad Ishaq Geer  17 , Kenneth Y Hartigan-Go  3   18 , François Houÿez  19 , Hansjörg Neth  16 , Gediminas Norgela  4 , Yaowares Oppamayun  20 , D K Theo Raynor  21 , Mehdi Bouhlel  13   22 , Federica Santoro  4 , Janet Sultana  23
Affiliations
Review

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

Priya Bahri et al. Drug Saf. 2023 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The views expressed in this report are the authors’ personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the employing organisations. Priya Bahri’s activity as the ISoP CommSIG Coordinator is pro bono in her personal capacity and time, outside the working hours of the European Medicines Agency as her employing organisation. She abstains from contributing to ISoP comments in response to public consultations of EU policies and projects.

Priya Bahri, Geoffrey Bowring, Brian D. Edwards, Angela Caro-Rojas, Bruce P.J. Hugman, Peter G. Mol, Katarina Ilic, Riadh Daghfous, Irene Fermont, Wolfgang Gaissmaier, Mohammad Ishaq Geer, François Houÿez, Hansjörg Neth, Gediminas Norgela, Yaowares Oppamayun, Mehdi Bouhlel, Federica Santoro and Janet Sultana have no conflicts of interests to declare. Christopher Anton receives an annual grant from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and owns shares in AstraZeneca, GlaxoSmithKline, BioNTech, Smith and Nephew, and Advanced Oncotherapy. Jeffrey K. Aronson has written articles and edited textbooks and has given medicolegal advice about adverse drug reactions. Giovanni Furlan is an employee of Pfizer s.r.l. and owns stocks in Pfizer, as well as other pharmaceutical companies through exchange traded funds. Kenneth Hartigan-Go declares that since 2018 he has been a respondent in legal cases in the Philippines involving the vaccine product Dengvaxia. D.K. Theo Raynor is co-founder and academic advisor to Luto Research, which was a spinout company of the University of Leeds, and develops, refines and tests health information; he is also co-chair of the Patient Safety Communication Advisory Panel at Bayer AG, Berlin. Gianluca Trifirò attended seminars and advisory boards funded by pharmaceutical companies on topics not related to the contents of this article, as head of a pharmacoepidemiological team at the University of Messina (until October 2020), and now of the academic spinoff INSPIRE, coordinated some observational studies and a Master’s programme, which received unconditional grants from several pharmaceutical companies; in addition, he participated in advisory boards that have been sponsored by several pharmaceutical companies; all these activities are not related to the topic of this article.

Figures

Fig. 1
Fig. 1
Infographics developed by the ISoP [17].Abbreviations: COVID-19 coronavirus disease 2019, ISoP International Society of Pharmacovigilance,WHO World Health Organization
See this image and copyright information in PMC

References

    1. Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG). https://isoponline.org/special-interest-groups/risk-communication-group/. Accessed 19 Sept 2020.
    1. Erice Declaration: effective communications in pharmacovigilance (report of the International Conference on Developing Effective Communications in Pharmacovigilance held in Erice, 24-27 September 1997, organised by the Uppsala Monitoring Centre (UMC), the Clinical Pharmacology Unit of Verona University, the International School of Pharmacology of the Ettore Majorana Centre for Scientific Culture in Erice, Italy and the World Health Organization, and supported by EQUUS Communications, London). Uppsala: UMC; 1997.
    1. Statement E. communication, medicines and patient safety (report of the Workshop on Drug Risk Communication held in Erice, 3–8 July 2009, organised by the International School of Pharmacology at the Ettore Majorana Foundation and Centre for Scientific Culture in Erice, Italy, in collaboration with the International Society of Pharmacovigilance (ISoP), the SK Foundation and the Uppsala Monitoring Centre (UMC)) Br J Clin Pharmacol. 2009;2010(69):207–208.
    1. Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, Hartigan-Go K, Hugman B, Mol PG; on behalf of the ISoP CommSIG. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance. Drug Saf. 2015; 38:621–27. - PubMed
    1. 14th Annual Meeting of ISoP. https://isoponline.org/annual-meetings/isop-2014-annual-meeting/. Accessed 30 Jan 2022.

MeSH terms